Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients.

Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, Barber J.

Mol Pharm. 2019 Feb 8. doi: 10.1021/acs.molpharmaceut.8b01189. [Epub ahead of print]

PMID:
30735053
2.

Assessing potential drug-drug interactions between dabigatran etexilate and a P-gp inhibitor in renal impairment population using PBPK modeling.

Doki K, Neuhoff S, Rostami-Hodjegan A, Homma M.

CPT Pharmacometrics Syst Pharmacol. 2019 Jan 18. doi: 10.1002/psp4.12382. [Epub ahead of print]

3.

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.

Polasek TM, Rostami-Hodjegan A, Yim DS, Jamei M, Lee H, Kimko H, Kim JK, Nguyen PTT, Darwich AS, Shin JG.

AAPS J. 2019 Jan 9;21(2):17. doi: 10.1208/s12248-018-0286-6.

PMID:
30627939
4.

Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics.

Couto N, Al-Majdoub ZM, Achour B, Wright PC, Rostami-Hodjegan A, Barber J.

Mol Pharm. 2019 Feb 4;16(2):632-647. doi: 10.1021/acs.molpharmaceut.8b00941. Epub 2019 Jan 18.

PMID:
30608694
5.

Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development.

Polasek TM, Rayner CR, Peck RW, Rowland A, Kimko H, Rostami-Hodjegan A.

Clin Pharmacol Drug Dev. 2018 Nov 30. doi: 10.1002/cpdd.638. [Epub ahead of print]

PMID:
30500115
6.

Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics.

Howard M, Barber J, Alizai N, Rostami-Hodjegan A.

Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1315-1330. doi: 10.1080/17425255.2018.1546288. Epub 2018 Nov 22. Review.

PMID:
30465453
7.

Response to "Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method".

Achour B, Rostami-Hodjegan A, Barber J.

J Proteome Res. 2018 Nov 20. doi: 10.1021/acs.jproteome.8b00871. [Epub ahead of print]

PMID:
30444614
8.

Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance.

Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A.

J Pharmacol Exp Ther. 2019 Feb;368(2):157-168. doi: 10.1124/jpet.118.251413. Epub 2018 Nov 9.

PMID:
30413628
9.

GASP and FASP are Complementary for LC-MS/MS Proteomic Analysis of Drug-Metabolizing Enzymes and Transporters in Pig Liver.

Howard M, Achour B, Al-Majdoub Z, Rostami-Hodjegan A, Barber J.

Proteomics. 2018 Dec;18(24):e1800200. doi: 10.1002/pmic.201800200. Epub 2018 Nov 30.

PMID:
30371990
10.

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.

Calvier EAM, Nguyen TT, Johnson TN, Rostami-Hodjegan A, Tibboel D, Krekels EHJ, Knibbe CAJ.

Pharm Res. 2018 Sep 14;35(11):209. doi: 10.1007/s11095-018-2487-1.

11.

Physiologically based pharmacokinetic modelling to guide drug delivery in older people.

Chetty M, Johnson TN, Polak S, Salem F, Doki K, Rostami-Hodjegan A.

Adv Drug Deliv Rev. 2018 Oct;135:85-96. doi: 10.1016/j.addr.2018.08.013. Epub 2018 Sep 4. Review.

12.

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.

Brussee JM, Yu H, Krekels EHJ, Palić S, Brill MJE, Barrett JS, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ.

Pharm Res. 2018 Jul 30;35(9):182. doi: 10.1007/s11095-018-2458-6.

13.

Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Standing JF, Anderson BJ, Hennig S, Holford NH, Johnston TN, Knibbe CAJ, Lonsdale DO, Rostami-Hodjegan A.

Clin Pharmacokinet. 2018 Nov;57(11):1471-1472. doi: 10.1007/s40262-018-0697-7. No abstract available.

PMID:
30027513
14.

Precision dosing in clinical medicine: present and future.

Polasek TM, Shakib S, Rostami-Hodjegan A.

Expert Rev Clin Pharmacol. 2018 Aug;11(8):743-746. doi: 10.1080/17512433.2018.1501271. Epub 2018 Jul 20. No abstract available.

PMID:
30010447
15.

Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.

Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB.

J Pharm Sci. 2018 Oct;107(10):2519-2530. doi: 10.1016/j.xphs.2018.06.013. Epub 2018 Jun 20.

PMID:
29935299
16.

First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.

Brussee JM, Yu H, Krekels EHJ, de Roos B, Brill MJE, van den Anker JN, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):374-383. doi: 10.1002/psp4.12295. Epub 2018 May 10.

17.

Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels.

Al Feteisi H, Al-Majdoub ZM, Achour B, Couto N, Rostami-Hodjegan A, Barber J.

J Neurochem. 2018 Sep;146(6):670-685. doi: 10.1111/jnc.14446. Epub 2018 Aug 1.

PMID:
29675872
18.

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz.

Chetty M, Cain T, Wedagedera J, Rostami-Hodjegan A, Jamei M.

Front Pharmacol. 2018 Mar 27;9:247. doi: 10.3389/fphar.2018.00247. eCollection 2018.

19.

Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5'-Diphosphate-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity.

Achour B, Dantonio A, Niosi M, Novak JJ, Al-Majdoub ZM, Goosen TC, Rostami-Hodjegan A, Barber J.

Drug Metab Dispos. 2018 Jun;46(6):805-812. doi: 10.1124/dmd.117.079475. Epub 2018 Mar 26.

PMID:
29581103
20.

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ.

Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19.

PMID:
29574693
21.

Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice: Drug-Drug and Food-Drug Interactions.

Hermann R, Derendorf H, von Richter O, Rostami-Hodjegan A.

J Clin Pharmacol. 2018 Jun;58(6):704-716. doi: 10.1002/jcph.1088. Epub 2018 Mar 7. No abstract available.

PMID:
29513896
22.

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.

Calvier EAM, Krekels EHJ, Yu H, Välitalo PAJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, van der Graaf PH, Danhof M, Knibbe CAJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):175-185. doi: 10.1002/psp4.12273. Epub 2018 Feb 5.

23.

Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2018 May;84(5):972-986. doi: 10.1111/bcp.13533. Epub 2018 Mar 6.

PMID:
29381228
24.

Revisiting Principles Behind Drug Clearance and Organ Extraction.

Rostami-Hodjegan A.

Clin Pharmacol Ther. 2018 Mar;103(3):388-389. doi: 10.1002/cpt.964. Epub 2017 Dec 20.

PMID:
29266230
25.

Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.

Abduljalil K, Johnson TN, Rostami-Hodjegan A.

Clin Pharmacokinet. 2018 Sep;57(9):1149-1171. doi: 10.1007/s40262-017-0618-1.

PMID:
29264787
26.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.

PMID:
29194718
27.

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.

Rostami-Hodjegan A.

Clin Pharmacol Ther. 2018 Feb;103(2):224-232. doi: 10.1002/cpt.904. Epub 2017 Nov 9.

28.

Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.

Doki K, Darwich AS, Patel N, Rostami-Hodjegan A.

Eur J Pharm Sci. 2017 Nov 15;109:111-120. doi: 10.1016/j.ejps.2017.07.035. Epub 2017 Aug 1.

29.

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.

Achour B, Dantonio A, Niosi M, Novak JJ, Fallon JK, Barber J, Smith PC, Rostami-Hodjegan A, Goosen TC.

Drug Metab Dispos. 2017 Oct;45(10):1102-1112. doi: 10.1124/dmd.117.076703. Epub 2017 Aug 2.

PMID:
28768682
30.

Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes.

Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer HM, Artursson P.

Mol Pharm. 2017 Sep 5;14(9):3142-3151. doi: 10.1021/acs.molpharmaceut.7b00364. Epub 2017 Aug 16.

31.

The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.

Musther H, Harwood MD, Yang J, Turner DB, Rostami-Hodjegan A, Jamei M.

J Pharm Sci. 2017 Sep;106(9):2826-2838. doi: 10.1016/j.xphs.2017.05.003. Epub 2017 May 8.

PMID:
28495566
32.

Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist.

Kusuhara H, Obach RS, Rostami-Hodjegan A, Pang KS, Hammarlund-Udenaes M, Derendorf H, Artursson P, Huang SM, Suzuki H, Terasaki T.

J Pharm Sci. 2017 Sep;106(9):2188-2194. doi: 10.1016/j.xphs.2017.04.072. Epub 2017 May 4. No abstract available.

PMID:
28479350
33.

Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes.

Achour B, Al Feteisi H, Lanucara F, Rostami-Hodjegan A, Barber J.

Drug Metab Dispos. 2017 Jun;45(6):666-675. doi: 10.1124/dmd.116.074732. Epub 2017 Apr 3.

PMID:
28373266
34.

Systems Toxicology: Real World Applications and Opportunities.

Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, Shah I, Wilks MF, Sturla SJ.

Chem Res Toxicol. 2017 Apr 17;30(4):870-882. doi: 10.1021/acs.chemrestox.7b00003. Epub 2017 Mar 31.

35.

Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?

Rostami-Hodjegan A, Tamai I, Pang KS.

Biopharm Drug Dispos. 2017 Mar;38(2):87-93. doi: 10.1002/bdd.2071. No abstract available.

PMID:
28317174
36.

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance.

Scotcher D, Billington S, Brown J, Jones CR, Brown CDA, Rostami-Hodjegan A, Galetin A.

Drug Metab Dispos. 2017 May;45(5):556-568. doi: 10.1124/dmd.117.075242. Epub 2017 Mar 7.

37.

Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project.

Lacy-Jones K, Hayward P, Andrews S, Gledhill I, McAllister M, Abrahamsson B, Rostami-Hodjegan A, Pepin X.

Comput Methods Programs Biomed. 2017 Mar;140:29-44. doi: 10.1016/j.cmpb.2016.11.006. Epub 2016 Nov 18.

PMID:
28254086
38.

Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.

Pade D, Jamei M, Rostami-Hodjegan A, Turner DB.

Biopharm Drug Dispos. 2017 Mar;38(2):94-114. doi: 10.1002/bdd.2072.

PMID:
28214380
39.
40.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
41.

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.

Scotcher D, Jones CR, Galetin A, Rostami-Hodjegan A.

J Pharmacol Exp Ther. 2017 Mar;360(3):484-495. doi: 10.1124/jpet.116.237438. Epub 2017 Jan 5.

42.

Quantifying gut wall metabolism: methodology matters.

Hatley OJ, Jones CR, Galetin A, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2017 Mar;38(2):155-160. doi: 10.1002/bdd.2062. Epub 2017 Feb 14. No abstract available.

43.

The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism.

Liu B, Crewe HK, Ozdemir M, Rowland Yeo K, Tucker G, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2017 Apr;38(3):260-270. doi: 10.1002/bdd.2058. Epub 2017 Feb 14.

PMID:
28004396
44.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:610-625. doi: 10.1016/j.ejps.2016.10.036. Epub 2016 Nov 2.

PMID:
27816631
45.

Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.

Olivares-Morales A, Ghosh A, Aarons L, Rostami-Hodjegan A.

AAPS J. 2016 Nov;18(6):1532-1549. Epub 2016 Sep 8.

PMID:
27631556
46.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:626-642. doi: 10.1016/j.ejps.2016.09.037. Epub 2016 Sep 28.

PMID:
27693299
47.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Margolskee A, Darwich AS, Pepin X, Pathak SM, Bolger MB, Aarons L, Rostami-Hodjegan A, Angstenberger J, Graf F, Laplanche L, Müller T, Carlert S, Daga P, Murphy D, Tannergren C, Yasin M, Greschat-Schade S, Mück W, Muenster U, van der Mey D, Frank KJ, Lloyd R, Adriaenssen L, Bevernage J, De Zwart L, Swerts D, Tistaert C, Van Den Bergh A, Van Peer A, Beato S, Nguyen-Trung AT, Bennett J, McAllister M, Wong M, Zane P, Ollier C, Vicat P, Kolhmann M, Marker A, Brun P, Mazuir F, Beilles S, Venczel M, Boulenc X, Loos P, Lennernäs H, Abrahamsson B.

Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

PMID:
27671970
48.

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Calvier EA, Krekels EH, Välitalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M, Knibbe CA.

Clin Pharmacokinet. 2017 Mar;56(3):273-285. doi: 10.1007/s40262-016-0436-x.

49.

Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.

Scotcher D, Jones C, Posada M, Galetin A, Rostami-Hodjegan A.

AAPS J. 2016 Sep;18(5):1082-94. doi: 10.1208/s12248-016-9959-1. Epub 2016 Aug 9. Review.

PMID:
27506526
50.

Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.

Chen R, Rostami-Hodjegan A, Wang H, Berk D, Shi J, Hu P.

Eur J Pharm Sci. 2016 Sep 20;92:131-6. doi: 10.1016/j.ejps.2016.07.001. Epub 2016 Jul 10.

PMID:
27412587

Supplemental Content

Loading ...
Support Center